Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2023-05-04 | 2023-04-06 |
| Drug Identification Number | 02333627 | 02333627 |
| Brand name | GLUCAGEN HYPOKIT | GLUCAGEN HYPOKIT |
| Common or Proper name | GLUCAGEN® HYPOKIT 1 MG | GLUCAGEN® HYPOKIT 1 MG |
| Company Name | NOVO NORDISK CANADA INC | NOVO NORDISK CANADA INC |
| Ingredients | GLUCAGON | GLUCAGON |
| Strength(s) | 1MG | 1MG |
| Dosage form(s) | POWDER FOR SOLUTION KIT | POWDER FOR SOLUTION KIT |
| Route of administration | INTRAMUSCULAR INTRAMUSCULAR | INTRAMUSCULAR INTRAMUSCULAR |
| Packaging size | EA | EA |
| ATC code | H04AA | H04AA |
| ATC description | GLYCOGENOLYTIC HORMONES | GLYCOGENOLYTIC HORMONES |
| Reason for shortage | Shortage of an inactive ingredient or component. | Shortage of an inactive ingredient or component. |
| Anticipated start date | 2023-04-10 | 2023-04-10 |
| Actual start date | ||
| Estimated end date | 2023-12-31 | 2023-12-31 |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | Yes | No |
| Company comments | Novo Nordisk A/S is experiencing an intermittent supply shortage of GlucaGen® HypoKit that will affect delivery in Canada. The cause of the intermittent supply shortage is a shortfall in the release and supply of pre-filled syringes from an external vendor, resulting in supply constraints for GlucaGen® HypoKit. The intermittent supply shortage is not a consequence of any safety or quality-related concerns. For any questions, please contact Novo Nordisk Canada’s main distributor, Paladin Labs (1-866-340-1112 paladincs@endo.com)”. | Novo Nordisk A/S is experiencing an intermittent supply shortage of GlucaGen® HypoKit that will affect delivery in Canada. The cause of the intermittent supply shortage is a shortfall in the release and supply of pre-filled syringes from an external vendor, resulting in supply constraints for GlucaGen® HypoKit. The intermittent supply shortage is not a consequence of any safety or quality-related concerns. For any questions, please contact Novo Nordisk Canada’s main distributor, Paladin Labs (1-866-340-1112 paladincs@endo.com)”. |
| Health Canada comments |